Notably, studies such as DAPA-HF and EMPEROR-Reduced have emphasized the significance of SGLT2 inhibitors as a fourth pillar in modifying the prognosis of HFrEF, thus complementing the gold standard treatment regimen [42]. This evidence concerns the gene SLC5A2 and hydrops fetalis.